Annaida Technologies has secured an oversubscribed Pre-Series A funding round led by HEMEX to support the commercialization of its innovative micro magnetic resonance technology in the fertility market.

Information on the Target

Annaida Technologies, a pioneering spin-off from the École Polytechnique Fédérale de Lausanne (EPFL), has made significant strides in the realm of micro magnetic resonance spectroscopy (micro-MRS). Their innovative approach enables researchers to conduct non-invasive chemical analyses at microscopic scales, making it possible to identify and measure compounds in living organisms ranging from 50 microns to 1 millimeter. The company's flagship device, Embryospin, has been adopted by leading academic institutions, contributing to the advancement of magnetic resonance research and generating initial revenue through research-oriented products.

Currently, Annaida Technologies is the beneficiary of the EIC Transition project HYPERCELL, which merges its micro-MRS technology with other groundbreaking methods to validate a benchtop tool for cell metabolic analysis. This advancement holds the potential to revolutionize cell research, allow for the exploration of individual cell metabolic profiles, and uncover previously hidden disease mechanisms as well as treatment responses.

Industry Overview in Switzerland

The life sciences sector in Switzerland is renowned for its cutting-edge research and innovation, significantly contributing to the country's economy and global standing. This industry encompasses a broad range of disciplines, including biotech